This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cencora (COR) Q4 Earnings Top, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Cencora's (COR) fourth-quarter fiscal 2023 results benefit from overall market growth, including rising demand for GLP-1 drugs approved for diabetes and weight loss. Inflationary pressure remains.
Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.
Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business
by Zacks Equity Research
Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business. It starts reporting under a new operating model.
DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Lowers '23 Guidance
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q3 revenues are driven by a rise in demand for aligners and CAD/CAM in the United States and a recovery in demand in China. Challenging macro headwinds linger.
Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
McKesson (MCK) Beats on Q2 Earnings, Raises '23 EPS View
by Zacks Equity Research
McKesson's (MCK) second-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.
CVS Health (CVS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Robust sales growth across all three operating segments drove CVS Health's (CVS) third-quarter results.
PacBio (PACB) Tops on Q3 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the third quarter, partly aided by customers' continued product transition to the Revio system.
Ecolab (ECL) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across all segments drives its third-quarter sales despite business challenges.
Top Stock Reports for JPMorgan Chase, Home Depot & Salesforce
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), The Home Depot, Inc. (HD) and Salesforce, Inc. (CRM).
Avantor (AVTR) Q3 Earnings In-Line With Estimates, Revenues Top
by Zacks Equity Research
Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft third-quarter performance.
Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View
by Zacks Equity Research
Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.
Integer Holdings (ITGR) Q3 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect robust Medical Sales, along with strength in the majority of the product lines.
Merit Medical (MMSI) Q3 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the third quarter.
DexCom (DXCM) Beats on Q3 Earnings, Raises Sales Outlook
by Zacks Equity Research
DexCom's (DXCM) third-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
CONMED (CNMD) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted third-quarter earnings and sales beat estimates on the back of strong growth in the U.S and international markets. Gross margin improves.
West Pharmaceutical (WST) Beats on Q3 Earnings, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results reflect a strong demand for non-COVID-19 demand, especially HVP devices.
Teladoc Health (TDOC) Q3 Loss Narrows on Integrated Care Strength
by Zacks Equity Research
Teladoc Health's (TDOC) Q3 results were aided by membership growth in the Integrated Care unit as well as strong BetterHelp revenues. Management presently expects 2023 net loss per share to be within $1.50-$1.40.
ZBH or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. ABT: Which Stock Is the Better Value Option?
5 Stocks to Watch on Solid Revenues in Last Reported Quarter
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths. These are: JPM, UNH, PG, ABT, FCX.
HCA Healthcare's (HCA) Q3 Earnings Miss on High Expense Level
by Zacks Equity Research
HCA Healthcare's (HCA) Q3 results were hurt by an increase in salaries and benefits expenses. Management presently estimates 2023 EPS to be within $17.80-$18.50, compared with the prior-view of $17.70-$18.90 per share.
Shockwave Medical (SWAV) Announces IVL Studies' Positive Results
by Zacks Equity Research
Shockwave Medical's (SWAV) latest announcement of two new publications validates the utility of IVL in complex nodular and eccentric calcium.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Company News for Oct 19, 2023
by Zacks Equity Research
Companies In The News Are: PG, ABT, STT, USB.
Geopolitical Conflicts in Middle-East in Focus
by Zacks Equity Research
Geopolitical Conflicts in Middle-East in Focus.